Evidence map›Paper›PMID 40199998›Full record

ArticleScientific reports2025

Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection.

Anna L Beukenhorst, Keira L Rice, Jacopo Frallicciardi, Martin H Koldijk, Carolyn M Boudreau, Justin Crawford, Lisette A H M Cornelissen, Kelly A S da Costa, Babette A de Jong, Stephanie Fischinger and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Anna L BeukenhorstDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. anna.beukenhorst@leydenlabs.com.
Keira L RiceLeyden Laboratories, Leiden, The Netherlands.
Jacopo FrallicciardiLeyden Laboratories, Leiden, The Netherlands.
Martin H KoldijkLeyden Laboratories, Leiden, The Netherlands.
Carolyn M BoudreauLeyden Laboratories, Leiden, The Netherlands.
Justin CrawfordLeyden Laboratories, Leiden, The Netherlands.
Lisette A H M CornelissenWageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands.
Kelly A S da CostaViral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of Greenwich, Chatham, UK.
Babette A de JongLeyden Laboratories, Leiden, The Netherlands.
Stephanie FischingerLeyden Laboratories, Leiden, The Netherlands.
Boris JulgLeyden Laboratories, Leiden, The Netherlands.
Jaco M KlapLeyden Laboratories, Leiden, The Netherlands.
Clarissa M KochLeyden Laboratories, Leiden, The Netherlands.
Zoltán MagyaricsLeyden Laboratories, Leiden, The Netherlands.
Faez A Nait MohamedThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Vintus OkonkwoThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Lindsey AdamsThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Caitlin M McCarthyThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Larance RonsardThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Nigel TempertonViral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of Greenwich, Chatham, UK.
Helene VietschLeyden Laboratories, Leiden, The Netherlands.
Kanin WichapongDepartment of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
Bertjan ZiereLeyden Laboratories, Leiden, The Netherlands.
Daniel LingwoodThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Jaap GoudsmitDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies have two core mechanisms of protection: an antibody's antigen-binding fragment (Fab) can bind and neutralize viral pathogens and its fragment crystallizable domain (Fc) catalyzes effector functions. We investigated the relative contribution of Fab- versus Fc-mediated mechanisms of protection through passive administration of distinct forms of the pan-reactive anti-influenza antibody CR9114. We demonstrated that the contribution of Fc-independent (Fab-dependent) versus Fc-dependent mechanisms of protection is defined by the route of administration. We used CR9114 variants (wild-type, two Fc-silenced variants, or the bivalent antigen-binding fragment F(ab')

Indexed as

Antibodies, MonoclonalAntibodies, ViralImmunoglobulin Fc FragmentsOrthomyxoviridae InfectionsAdministration, IntranasalAnimalsFemaleHumansImmunoglobulin Fab FragmentsInfluenza B virusMiceAntibodies, MonoclonalAntibodies, ViralImmunoglobulin Fab FragmentsImmunoglobulin Fc Fragments

Identifiers

PMID40199998
PMCPMC11978755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.